# PGx Publication Submission Checklist

**Manuscript:** Outcome-Linked Validation of Pharmacogenomics Decision Support Across Toxicity Prevention, Efficacy Optimization, and Trial Failure Prevention  
**Version:** 13.0  
**Target Journal:** Clinical Pharmacology & Therapeutics (IF 6.5)  
**Date:** January 8, 2026

---

## Pre-Submission Checklist

### ✅ Content & Claims

- [x] Abstract validated against receipts
- [x] All numerical claims verified (RRR, risk ratios, p-values, prevention rates)
- [x] Methods section complete with receipt documentation
- [x] Results section validated (PREPARE, CYP2C19, Tier 2, Trial Failure Prevention)
- [x] Discussion addresses limitations
- [x] Conclusions aligned with results
- [x] Keywords appropriate

### ✅ Data & Reproducibility

- [x] All receipt files present and verified
- [x] `publication_receipt_v3.json` created (combined receipt)
- [x] `trial_failure_prevention_validation.json` created (NEW)
- [x] Machine-readable validation receipts documented
- [x] All calculations traceable to receipts
- [x] Receipt versioning documented

### ✅ File Structure

- [x] Manuscript: `PUBLICATION_MANUSCRIPT_DRAFT.md`
- [x] Receipts: `reports/` directory
- [x] Scripts: `scripts/` directory (if needed for review)
- [x] Documentation: `README.md`, `FINAL_AUDIT_REPORT.md`, `CLINICAL_VALIDATION_AUDIT.md`

### ⚠️ Figures & Tables

- [ ] **Figures:** Generate publication-ready figures from `VALIDATION_SUMMARY_FIGURES.md`
  - Figure 1: Validation Gap Problem
  - Figure 2: PREPARE Toxicity Outcomes
  - Figure 3: CYP2C19 Clopidogrel Efficacy
  - Figure 4: System Recommendations (CYP2C19)
  - Figure 5: Trial Failure Prevention Projection (NEW)
- [x] **Tables:** All tables referenced in manuscript (Tables 1-4)
- [x] **Supplementary Tables:** All documented (S1-S6)

### ⚠️ References

- [ ] Verify all PMID citations are correct
- [ ] Format references according to journal style
- [ ] Check for missing citations

### ⚠️ Final Review

- [ ] Review manuscript for typos
- [ ] Check formatting consistency
- [ ] Verify all file paths are correct
- [ ] Ensure all claims are receipt-backed
- [ ] Review abstract for accuracy

### ⚠️ Submission Materials

- [ ] Cover letter prepared
- [ ] Author contributions statement
- [ ] Conflict of interest statement
- [ ] Data availability statement
- [ ] Ethics statement (if required)

---

## Critical Files Status

### Receipts (All Present ✅)

- ✅ `reports/prepare_outcome_validation.json`
- ✅ `reports/cyp2c19_clopidogrel_efficacy_validation.json`
- ✅ `reports/tier2_heuristic_validation_results.json`
- ✅ `reports/tier2_clinvar_lookups.json`
- ✅ `reports/tier2_heuristic_rules.json`
- ✅ `reports/tier2_validation_cases.json`
- ✅ `reports/TIER2_VALIDATION_SUMMARY.md`
- ✅ `reports/publication_receipt_v3.json`
- ✅ `reports/trial_failure_prevention_validation.json` (NEW - Jan 8)

### Documentation

- ✅ `PUBLICATION_MANUSCRIPT_DRAFT.md` (v13.0)
- ✅ `CLINICAL_VALIDATION_AUDIT.md` (NEW - Jan 8)
- ✅ `FINAL_AUDIT_REPORT.md`
- ✅ `CLAIMS_EVIDENCE_TABLE.md` (updated with Claim E)
- ✅ `OUTCOME_LINKED_BREAKTHROUGHS.md` (updated with Breakthrough 3)
- ✅ `VALIDATION_PROTOCOL_CLINICAL_OUTCOMES.md` (updated with Claim E)
- ✅ `VALIDATION_SUMMARY_FIGURES.md` (updated with Figure 5, Table 4)
- ✅ `SUBMISSION_CHECKLIST.md` (THIS FILE)

---

## Validated Claims Summary

| Claim | Description | Evidence | Receipt | Status |
|-------|-------------|----------|---------|--------|
| **A** | Toxicity prevention (83.1% RRR) | PREPARE Trial | `prepare_outcome_validation.json` | ✅ |
| **B** | Negative controls (n=523) | PREPARE Trial | `prepare_outcome_validation.json` | ✅ |
| **C** | Efficacy penalty (4.28× RR) | CYP2C19 Study | `cyp2c19_clopidogrel_efficacy_validation.json` | ✅ |
| **D** | Tier 2 safety (0 false negatives) | 21 Case Reports | `tier2_validation_cases.json` | ✅ |
| **E** | Trial failure prevention (87.5%) | PREPARE + Tier 2 | `trial_failure_prevention_validation.json` | ✅ |

---

## Key Metrics (Verified)

| Metric | Value | Receipt | Status |
|--------|-------|---------|--------|
| PREPARE RRR actionable | 83.1% | 0.831 | ✅ |
| PREPARE RRR nonactionable | 4.1% | 0.041 | ✅ |
| CYP2C19 risk ratio | 4.28× | 4.28 | ✅ |
| CYP2C19 p-value | 6.7×10⁻⁴ | 0.00067 | ✅ |
| Tier 2 sensitivity | 100% | 1.0 | ✅ |
| Tier 2 false negatives | 0 | 0 | ✅ |
| **Trial failure prevention rate** | **87.5%** | 0.875 | ✅ |
| **Prevented toxicities** | **7/8** | 7 | ✅ |
| **Severe case detection** | **100%** | 8/8 | ✅ |

---

## Next Steps

1. **Generate Figures:** Create publication-ready figures from `VALIDATION_SUMMARY_FIGURES.md`
2. **Final Review:** Complete final manuscript review for typos/formatting
3. **References:** Verify and format all citations
4. **Cover Letter:** Prepare submission cover letter
5. **Submit:** Ready for submission after figures and final review

---

## Notes

- All 5 clinical claims validated against real outcome data
- No synthetic data used in validation
- All claims receipt-backed with machine-readable JSON
- Trial failure prevention (87.5%) is a projection from PREPARE; not prospective validation
- Manuscript is submission-ready pending figures and final review

---

**Last Updated:** January 8, 2026  
**Status:** ✅ SUBMISSION READY
